Radiographic Progression of Patients with Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study

Arthritis Care and Research

Volumn 68, Issue 2, 2016, Pages 267-274

  Kavanaugh, Arthur ^a   Van Der Heijde, Désirée ^b   Beutler, Anna ^c   Gladman, Dafna ^d   Mease, Philip ^e,i   Krueger, Gerald G ^f   McInnes, Iain B ^g   Helliwell, Philip ^h   Coates, Laura C ^h   Xu, Stephen ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY OF TORONTO   (Canada)

^e SWEDISH MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL DISEASE ACTIVITY; OPEN STUDY; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; RADIOGRAPHY; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; HUMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84957110503     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22576     Document Type: Article

References (18)

1. Olivieri I, D'Angelo S, Palazzi C, Padula A., Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014; 10: 531-42.
2. Coates LC, Fransen J, Helliwell PS., Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
3. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al., Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73: 6-16.
4. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al., Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016-24.
5. Coates LC, Helliwell PS., Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62: 965-9.
6. Coates LC, Cook R, Lee KA, Chandran V, Gladman DD., Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010; 62: 970-6.
7. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al., Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-86.
8. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al., Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64: 2504-17.
9. Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, van der Heijde D, et al., Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013; 72: 1777-85.
10. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, et al., Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014; 73: 1689-94.
11. Fredriksson T, Pettersson U., Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
12. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
13. Fries JF, Spitz PW, Young DY., The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789-93.
14. Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al., Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
15. Van der Heijde D, Sharp J, Wassenberg S, Gladman DD., Psoriatic arthritis imaging: a review of scoring methods [review]. Ann Rheum Dis 2005; 64 (Suppl II): ii61-4.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al., Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
18. Iervolino S, Di Minno MN, Peluso R, Lofrano M, Russolillo A, Di Minno G, et al., Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012; 39: 568-73.